Shares of Intel Corporation (NASDAQ:INTC) [Trend Analysis] swings enthusiastically in regular trading session, it an advance of 0.20% to close at $35.51. At Intel’s recent AI Day, the chipmaker previewed a series of future products that it intends to use to unseat GPUs as the de facto standard for machine learning. The one-day event was Intel’s most assertive pronouncement of its intentions to become a major player in the artificial intelligence market.
Perhaps the most surprising element of the roadmap is the productization of the Nervana Engine, the machine learning chip that Nervana engineers were working on previous to Intel’s acquisition of the firm earlier this year. Given Intel’s devotion to Xeon Phi, we at TOP500 News were over a little skeptical that the firm would ever commercialize the Nervana dereaches into. But that is apparently the plan.
In the first half of 2017, the chipmaker intends to produce first silicon of “Lake Crest,” a deep learning accelerator that is purpose-built to train neural networks. The design is derived directly from the Nervana Engine, right down the second-generation high bandwidth memory (HBM2), which will be integrated on the package. From software memory management to eclectic math, there is nothing general-purpose about this chip. Moving forward to saw long-term intention, the experts calculate Return on Investment of 13.60%. The stock is going forward its fifty-two week low with 31.36% and lagging behind from its 52-week high price with -6.73%. INTC last month stock price volatility remained 1.55%.
Edwards Lifesciences Corp. (NYSE:EW) [Trend Analysis] retains strong position in active trade, as shares scoring -1.75% to $84.30 in a active trade session, while looking at the shares volume, about 3.08 Million shares have changed hands in this session. Medical technology firm, Edwards Lifesciences Corp. (EW) reported that it has agreed to takeover Israel-based Valtech Cardio Ltd. The purchase price is $340 million in stock and cash at closing, with the potential for up to $350 million in additional pre-specified milestone-driven payments over the next 10 years.
Valtech Cardio is a privately held developer of the Cardioband System for transcatheter repair of the mitral and tricuspid valves. The Cardioband System is not agreed for sale in the United States. Previous to the close of the accord, which remains subject to customary closing conditions and is predictable in early 2017, Valtech will spin off its early-stage transseptal mitral valve replacement technology program. Edwards will retain an option to takeover that program and its associated intellectual property. The firm has institutional ownership of 86.20%, while insider ownership included 0.20%. EW attains analyst recommendation of 2.00 with week’s performance of -5.31%. Investors looking additional ahead will note that the Price to next year’s EPS is 18.37%.